PL376017A1 - Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy poprzez zwiększanie liczby wysepek komórek Langerhansa - Google Patents

Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy poprzez zwiększanie liczby wysepek komórek Langerhansa

Info

Publication number
PL376017A1
PL376017A1 PL03376017A PL37601703A PL376017A1 PL 376017 A1 PL376017 A1 PL 376017A1 PL 03376017 A PL03376017 A PL 03376017A PL 37601703 A PL37601703 A PL 37601703A PL 376017 A1 PL376017 A1 PL 376017A1
Authority
PL
Poland
Prior art keywords
kynurenine
islets
diabetes
increasing
treatment
Prior art date
Application number
PL03376017A
Other languages
English (en)
Inventor
Micheline Kergoat
Catherine Kargar
Valerie Autier
De Vacqueur Annick Arbellot
Gerard Moinet
Dominique Marais
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0300107A external-priority patent/FR2849599B1/fr
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of PL376017A1 publication Critical patent/PL376017A1/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A61K31/06—Phenols the aromatic ring being substituted by nitro groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL03376017A 2003-01-07 2003-12-18 Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy poprzez zwiększanie liczby wysepek komórek Langerhansa PL376017A1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0300107A FR2849599B1 (fr) 2003-01-07 2003-01-07 Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete
FR0314263A FR2849598B1 (fr) 2003-01-07 2003-12-04 Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans

Publications (1)

Publication Number Publication Date
PL376017A1 true PL376017A1 (pl) 2005-12-12

Family

ID=32598906

Family Applications (2)

Application Number Title Priority Date Filing Date
PL378212A PL378212A1 (pl) 2003-01-07 2003-12-18 Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy
PL03376017A PL376017A1 (pl) 2003-01-07 2003-12-18 Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy poprzez zwiększanie liczby wysepek komórek Langerhansa

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL378212A PL378212A1 (pl) 2003-01-07 2003-12-18 Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy

Country Status (17)

Country Link
US (2) US7727977B2 (pl)
EP (2) EP1581216A1 (pl)
JP (2) JP2006515594A (pl)
KR (2) KR20050090443A (pl)
AR (2) AR042712A1 (pl)
AT (1) ATE457725T1 (pl)
AU (2) AU2003293937B2 (pl)
BR (2) BR0317947A (pl)
CA (2) CA2512563C (pl)
DE (1) DE60331359D1 (pl)
ES (1) ES2339656T3 (pl)
FR (1) FR2849598B1 (pl)
MX (2) MXPA05007292A (pl)
PL (2) PL378212A1 (pl)
RU (2) RU2351329C2 (pl)
TW (2) TW200418820A (pl)
WO (2) WO2004060369A1 (pl)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
EP2054056A4 (en) 2006-08-16 2010-08-25 J David Gladstone Inst A Testa SMALL MOLECULAR INHIBITORS OF KYNURENINE-3-MONOOXYGENASE
DK2054397T3 (en) 2006-08-16 2016-01-18 J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone SMALL MOLECULAR INHIBITORS OF KYNURENIN-3-MONOOXYGENASE
EP2214659B1 (en) * 2007-12-03 2011-08-31 Merck Patent GmbH Use of 4-oxobutanoic acid derivatives in the treatment of pathologies associated with immunological disorders
JP5597555B2 (ja) 2008-03-12 2014-10-01 ユニバーシティー・オブ・マイアミ 低血糖症を治療するための医薬品の製造におけるグルカゴン放出を刺激する化合物の使用
PL228037B1 (pl) * 2009-03-23 2018-02-28 Marciniak Agnieszka Maria Zastosowanie kwasu kynureninowego w zapobieganiu lub leczeniu chorób trzustki
CA2784899A1 (en) * 2009-12-30 2011-07-07 Avon Products, Inc. Topical lightening composition and uses thereof
RU2592694C2 (ru) 2010-08-18 2016-07-27 СЭМЬЮМЕД, ЭлЭлСи Дикетоны и гидроксикетоны в качестве активатора сигнального пути катенина
DK2968249T3 (en) 2013-02-22 2019-03-04 Samumed Llc GAMMA DIKETONS AS WNT / BETA-CATENIN SIGNAL ROAD ACTIVATORS
MA40454B1 (fr) 2014-08-20 2020-01-31 Samumed Llc Gamma-dicétones pour le traitement et la prévention des rides et du vieillissement de la peau
WO2016044922A1 (en) 2014-09-26 2016-03-31 The University Of British Columbia A combination of kynurenine and antigen presenting cells (apc) as therapeutics and methods for their use in immune modulation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181474A (en) * 1978-03-02 1980-01-01 Dunham-Bush, Inc. Vertical axis hermetic rotary helical screw compressor with improved rotary bearings and oil management
US5527537A (en) * 1992-05-18 1996-06-18 Dietl; Hans Pharmaceutical preparation containing cyclosporine(s) for intravenous administration and a process for its production
ATE161730T1 (de) * 1993-02-09 1998-01-15 Biogen Inc Antikörper zur behandlung von insulinabhängigen diabetes
EP0685039B1 (en) * 1993-12-22 2000-03-08 Entropy Systems, Inc. Device and method for thermal transfer using air as the working medium
GB9522617D0 (en) * 1995-11-03 1996-01-03 Pharmacia Spa 4-Phenyl-4-oxo-butenoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
GB9522615D0 (en) * 1995-11-03 1996-01-03 Pharmacia Spa 4-Phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
CN1216522A (zh) * 1996-02-19 1999-05-12 日本烟草产业株式会社 糖尿病治疗剂
JP3104966B2 (ja) * 1996-02-19 2000-10-30 日本たばこ産業株式会社 糖尿病治療薬
US5877193A (en) * 1996-07-19 1999-03-02 Hoffmann-La Roche Inc. Use of N-(4-aryl-thiazol-2-yl)-sulfonamides
FR2752422B1 (fr) * 1996-08-16 1998-11-06 Lipha Composition pharmaceutique contenant des acides 4-oxo-butanoiques
US6288063B1 (en) * 1998-05-27 2001-09-11 Bayer Corporation Substituted 4-biarylbutyric and 5-biarylpentanoic acid derivatives as matrix metalloprotease inhibitors
US6572542B1 (en) * 2000-03-03 2003-06-03 Medtronic, Inc. System and method for monitoring and controlling the glycemic state of a patient
SE0001899D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
AU2001291579B2 (en) * 2000-09-29 2006-08-31 Viron Therapeutics Inc. Use of serp- 1 in combination with an immunosuppressant for influencing inflammatory and immune reactions
FR2849598B1 (fr) * 2003-01-07 2006-09-22 Merck Sante Sas Utilisation d'inhibiteurs de la kynurenine-3-hydroxylase pour le traitement du diabete, par augmentation du nombre de cellules des ilots de langerhans
TW200920357A (en) * 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety

Also Published As

Publication number Publication date
JP2006516960A (ja) 2006-07-13
AU2003293937A1 (en) 2004-07-29
FR2849598A1 (fr) 2004-07-09
WO2004060369A1 (en) 2004-07-22
JP4813800B2 (ja) 2011-11-09
AU2003293937B2 (en) 2009-03-26
EP1581215A1 (en) 2005-10-05
FR2849598B1 (fr) 2006-09-22
AU2003296679A1 (en) 2004-07-29
EP1581215B1 (en) 2010-02-17
WO2004060368A1 (en) 2004-07-22
US20060142358A1 (en) 2006-06-29
WO2004060369A8 (en) 2005-07-07
ATE457725T1 (de) 2010-03-15
US20060052456A1 (en) 2006-03-09
AR043327A1 (es) 2005-07-27
US7727977B2 (en) 2010-06-01
AR042712A1 (es) 2005-06-29
DE60331359D1 (de) 2010-04-01
RU2351329C2 (ru) 2009-04-10
PL378212A1 (pl) 2006-03-20
EP1581216A1 (en) 2005-10-05
CA2512558A1 (en) 2004-07-22
JP2006515594A (ja) 2006-06-01
TW200418820A (en) 2004-10-01
BR0317950A (pt) 2005-11-29
CA2512563A1 (en) 2004-07-22
TW200503676A (en) 2005-02-01
MXPA05007292A (es) 2005-09-08
KR20050090447A (ko) 2005-09-13
ES2339656T3 (es) 2010-05-24
RU2005125086A (ru) 2006-08-27
RU2005125085A (ru) 2006-03-20
KR20050090443A (ko) 2005-09-13
CA2512563C (en) 2012-06-19
BR0317947A (pt) 2005-11-29
MXPA05007293A (es) 2005-09-08

Similar Documents

Publication Publication Date Title
ZA200803701B (en) Modulators of ATP-binding Cassette transporters
LT2489659T (lt) Atp rišančios kasetės transporterių moduliatoriai
IL185277A0 (en) Pharmaceutical compositions containing roflumilast for the treatment of diabetes
IL179674A0 (en) Chemical compounds and pharmaceutical compositions containing them for the treatment of inflammatory disorders
IL190951A0 (en) Method of acting upon organism by targeted delivery of biologicaly active substances into mitochondria, pharmaceutical composition for carrying out said method, and compound used for the purpose
WO2007115305A3 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
EP1991218A4 (en) USE OF CYCLOLIGNANS IN THE TREATMENT OF TYPE 2 DIABETES AND AS CONTRACEPTIVES
HUE041944T2 (hu) Alacsony dózisú imiquimod készítmények és rövid adagolási módszer aktinikus keratózis kezelésére
PT1781272T (pt) Utilização de compostos ativos no recetor sigma para o tratamento de alodinia mecânica
PL2086932T3 (pl) Podstawione związki arylo-indoli i ich metabolity kynurenino/kynuramino podobne jako środki lecznicze
PL376017A1 (pl) Inhibitory 3-hydroksylazy kynureninowej do leczenia cukrzycy poprzez zwiększanie liczby wysepek komórek Langerhansa
NO20090724L (no) Benzylaminer, fremgangsmåte for fremstilling av slike, og anvendelse av dem som betennelseshemmende midler
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
WO2005072713A3 (en) Cholinesterase inhibitors for treating inflammation
EP1815865A4 (en) THERAPEUTIC AGENT AGAINST DIABETES WITH A PROTEASE-INHIBITING COMPOUND
ZA200808363B (en) Compounds and methods for diagnosis and treatment of leishmaniasis
EP1881756A4 (en) TREATMENT OF DISEASES OF THE MICROVASCULAR SYSTEM WITH ACETYLCHOLINESTERASE INHIBITORS
AP2413A (en) 5-phenyl-pentanoic acid derivatives as matrix metalloproteinase inhibitors for the treatment of asthma and other disease.
PL1811866T3 (pl) Zastosowanie związków przeciwutleniających przy uszkodzeniach mięśni
SI1872796T1 (sl) Transdermalni pripravek za zunanjo uporabo, ki vsebuje nesteroidno protivnetno/analgetično sredstvo
BRPI0820210A2 (pt) composto, composição farmacêutica, uso de um composto, e, método de tratamento terapêutico de um mamífero.
EP1750698A4 (en) 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES
PL1597965T3 (pl) Typ brokuła przystosowany do łatwego zbioru
DK1853609T3 (da) Thienopyridinderivater og anvendelse deraf som hsp90-modulatorer
FI20041388A0 (fi) Ainakin yhden vetyisotoopin käsittävien substraattien valmistus

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)